Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021

Overcoming COVID-19 Investigators

doi:10.15585/MMWR.MM7042E1

Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021

Overcoming COVID-19 Investigators

Research output: Contribution to journal › Article › peer-review

79 Scopus citations

Abstract

What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.

Original language	English (US)
Pages (from-to)	1483-1488
Number of pages	6
Journal	Morbidity and Mortality Weekly Report
Volume	70
Issue number	42
DOIs	https://doi.org/10.15585/MMWR.MM7042E1
State	Published - 2021
Externally published	Yes

ASJC Scopus subject areas

Epidemiology
Health(social science)
Health, Toxicology and Mutagenesis
Health Information Management

Access to Document

10.15585/MMWR.MM7042E1

Cite this

@article{1037fefd468c46f5a4bbf483d8285803,

title = "Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021",

abstract = "What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.",

author = "{Overcoming COVID-19 Investigators} and Olson, {Samantha M.} and Newhams, {Margaret M.} and Halasa, {Natasha B.} and Price, {Ashley M.} and Boom, {Julie A.} and Sahni, {Leila C.} and Katherine Irby and Walker, {Tracie C.} and Schwartz, {Stephanie P.} and Pannaraj, {Pia S.} and Maddux, {Aline B.} and Bradford, {Tamara T.} and Nofziger, {Ryan A.} and Boutselis, {Benjamin J.} and Cullimore, {Melissa L.} and Mack, {Elizabeth H.} and Schuster, {Jennifer E.} and Gertz, {Shira J.} and Cvijanovich, {Natalie Z.} and Michele Kong and Cameron, {Melissa A.} and Staat, {Mary A.} and Levy, {Emily R.} and Chatani, {Brandon M.} and Kathleen Chiotos and Zambrano, {Laura D.} and Campbell, {Angela P.} and Patel, {Manish M.} and Randolph, {Adrienne G.}",

year = "2021",

doi = "10.15585/MMWR.MM7042E1",

language = "English (US)",

volume = "70",

pages = "1483--1488",

journal = "Morbidity and Mortality Weekly Report",

issn = "0149-2195",

publisher = "Department of Health and Human Services",

number = "42",

}

TY - JOUR

T1 - Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021

AU - Overcoming COVID-19 Investigators

AU - Olson, Samantha M.

AU - Newhams, Margaret M.

AU - Halasa, Natasha B.

AU - Price, Ashley M.

AU - Boom, Julie A.

AU - Sahni, Leila C.

AU - Irby, Katherine

AU - Walker, Tracie C.

AU - Schwartz, Stephanie P.

AU - Pannaraj, Pia S.

AU - Maddux, Aline B.

AU - Bradford, Tamara T.

AU - Nofziger, Ryan A.

AU - Boutselis, Benjamin J.

AU - Cullimore, Melissa L.

AU - Mack, Elizabeth H.

AU - Schuster, Jennifer E.

AU - Gertz, Shira J.

AU - Cvijanovich, Natalie Z.

AU - Kong, Michele

AU - Cameron, Melissa A.

AU - Staat, Mary A.

AU - Levy, Emily R.

AU - Chatani, Brandon M.

AU - Chiotos, Kathleen

AU - Zambrano, Laura D.

AU - Campbell, Angela P.

AU - Patel, Manish M.

AU - Randolph, Adrienne G.

PY - 2021

Y1 - 2021

N2 - What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.

AB - What is already known about this topic? Persons aged 12–18 years are eligible to receive COVID-19 vaccine. Currently, data are lacking on real-world vaccine effectiveness against COVID-19 hospitalization in adolescents. What is added by this report? Among hospitalized U.S. patients aged 12–18 years, vaccine effectiveness of 2 doses of Pfizer-BioNTech vaccine against COVID-19 hospitalization during June–September 2021, was 93% (95% confidence interval = 83%–97%). What are the implications for public health practice? This evaluation demonstrated that 2 doses of Pfizer-BioNTech vaccine were highly effective in preventing COVID-19 hospitalization among persons aged 12–18 years. Findings reinforce the importance of vaccination to protect U.S. youths against severe COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85118796387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118796387&partnerID=8YFLogxK

U2 - 10.15585/MMWR.MM7042E1

DO - 10.15585/MMWR.MM7042E1

M3 - Article

C2 - 34673751

AN - SCOPUS:85118796387

SN - 0149-2195

VL - 70

SP - 1483

EP - 1488

JO - Morbidity and Mortality Weekly Report

JF - Morbidity and Mortality Weekly Report

IS - 42

ER -

Effectiveness of Pfizer-BioNTech mRNA Vaccination against COVID-19 Hospitalization among Persons Aged 12–18 Years — United States, June–September 2021

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this